The HLA-E peptidome in HIV infection
The HLA-E peptidome in HIV infection
批准号:
9411277
负责人:
Sylvie Le Gall
金额:
$25.65万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-14 至 2019-06-30
关键词:
AllelesAnimalsAntigen Presentation PathwayAntigensAreaAttenuatedBindingCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCD8B1 geneCD94 AntigenCellsCellular StressCollaborationsComputer AnalysisCytolysisCytomegalovirusCytotoxic T-LymphocytesEpitopesHIVHIV AntigensHIV GenomeHIV InfectionsHIV vaccineHLA-A geneHaplotypesHepatitis CHot SpotHumanImmuneImmune TargetingImmune ToleranceImmune responseIndividualInfectionInstitutesKLRD1 geneLeadLengthMass Spectrum AnalysisMosaicismMycobacterium tuberculosisNatural Killer CellsNaturePeptide Signal SequencesPeptide/MHC ComplexPeptidesPersonsPopulationProteinsProteomeReading FramesResearchRoleSIVSIV VaccinesSalmonellaSamplingSequence HomologySurfaceT cell responseT-LymphocyteTestingTimeVaccine DesignVaccinesVariantVirusWalkersbiochemical toolscell typecohortcomputerized toolscytotoxicitydensitydesignimmune clearanceinterestkillingsnovelpathogenreceptorresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
The diversity of HIV sequences and the highly polymorphic nature of MHC-Ia (HLA-A/B/C allomorphs) lead to a
highly heterogeneous display of HIV peptides across individuals and create a major obstacle for the design of
HIV vaccines. While the diversity of HIV sequences can be overcome through the design of mosaic antigens or
immunogens focused on conserved areas of the HIV proteome, the diversity of MHC-Ia is unavoidable. HLA-E
is a non-classical MHC-Ib molecule highly conserved among humans (only 2 conserved alleles) that was
originally identified for its role in immune tolerance. In 2016 two studies provided the first evidence of
cytolytic immune responses against MHC-E-restricted HIV/SIV peptides. They showed broad CD8 T cell
immune responses against MHC-E-restricted SIV peptides in a vaccine setting, and cytolytic NK response
triggered by one HIV Gag peptide displayed by HLA-E and blocking inhibitory NKG2A receptor (the latter from
collaborator Dr Barker and coauthored by the PI).
An HLA-E-directed vaccine strategy would be applicable to the population regardless of the MHC-Ia diversity.
However HIV peptides displayed by HLA-E in HIV-infected CD4 T cells have not been identified as the only
known HIV binder was imputed by sequence homology. This R21 proposal tests the hypothesis that HIV-
infected CD4 T cells display a diverse set of HLA-E-restricted HIV peptides targetable by various HLA-E
restricted cytolytic immune responses.
We developed mass spectrometry approaches and computational tools to identify self- and virus-derived
intracellular and MHC-bound peptides from various cell types, including HIV-infected primary CD4 T cells.
These HIV peptides include known HIV epitopes, peptides of non-canonical lengths, peptides derived from
alternate reading frames of HIV genome, and uncovered novel T cell immune responses. The coverage of the
HIV proteome by MHC-peptides in various types of infected cells is uneven, includes common hot spots of
nested MHC-bound peptides, which do not correlate with the density of known HIV immune responses. This
suggests that the immune responses elicited in natural HIV infection do not fully cover the HIV peptidome
displayed by infected cells. Only a direct analysis of HLA-E-bound peptides will identify relevant targets for
immune recognition, including peptides generated from alternate reading frames of HIV proteins.
Here we propose to 1) define the HLA-E peptidome presented by HIV-infected CD4 T cells, 2) Identify HLA-E-
restricted cytolytic immune responses against HIV (including CD8/4 T cells and NK cells).
This proposal builds on the PI's expertise in HIV antigen processing and presentation, long-time collaborator
Dr Heckerman from Microsoft Research for computational analysis of HLA-E peptides, collaborator Dr Barker
for expertise in NK cells, and Dr Walker for CD8 T cells expertise and access to a large cohort of HIV+ donors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Learning from attenuated CMV how to broaden HIV-specific T cell responses
-
批准号:8895261
-
项目类别:
-
资助金额:$54.88万
-
财政年份:2014
-
负责人:Sylvie Le Gall
-
依托单位:
Learning from attenuated CMV how to broaden HIV-specific T cell responses
-
批准号:8732086
-
项目类别:
-
资助金额:$53.14万
-
财政年份:2014
-
负责人:Sylvie Le Gall
-
依托单位:
Mechanisms and optimization of epitope presentation by HIV-infectable cell subset
-
批准号:8141719
-
项目类别:
-
资助金额:$18.83万
-
财政年份:2010
-
负责人:Sylvie Le Gall
-
依托单位:
Immune responses against HIV-induced cell-derived neoepitopes and HIV control
-
批准号:8316386
-
项目类别:
-
资助金额:$51.3万
-
财政年份:2009
-
负责人:Sylvie Le Gall
-
依托单位:
Mechanisms and optimization of epitope presentation by HIV-infectable cell subset
-
批准号:8127882
-
项目类别:
-
资助金额:$43.37万
-
财政年份:2009
-
负责人:Sylvie Le Gall
-
依托单位:
Immune responses against HIV-induced cell-derived neoepitopes and HIV control
-
批准号:8130699
-
项目类别:
-
资助金额:$51.32万
-
财政年份:2009
-
负责人:Sylvie Le Gall
-
依托单位:
Immune responses against HIV-induced cell-derived neoepitopes and HIV control
-
批准号:7736994
-
项目类别:
-
资助金额:$50.81万
-
财政年份:2009
-
负责人:Sylvie Le Gall
-
依托单位:
Mechanisms and optimization of epitope presentation by HIV-infectable cell subset
-
批准号:8318037
-
项目类别:
-
资助金额:$43.37万
-
财政年份:2009
-
负责人:Sylvie Le Gall
-
依托单位:
Mechanisms and optimization of epitope presentation by HIV-infectable cell subset
-
批准号:8523758
-
项目类别:
-
资助金额:$40.77万
-
财政年份:2009
-
负责人:Sylvie Le Gall
-
依托单位:
Mechanisms and optimization of epitope presentation by HIV-infectable cell subset
-
批准号:7934644
-
项目类别:
-
资助金额:$43.81万
-
财政年份:2009
-
负责人:Sylvie Le Gall
-
依托单位:
Immune responses against HIV-induced cell-derived neoepitopes and HIV control
-
批准号:7920249
-
项目类别:
-
资助金额:$51.84万
-
财政年份:2009
-
负责人:Sylvie Le Gall
-
依托单位:
Mechanisms and optimization of epitope presentation by HIV-infectable cell subset
-
批准号:7760502
-
项目类别:
-
资助金额:$44.23万
-
财政年份:2009
-
负责人:Sylvie Le Gall
-
依托单位:
Role of antigen processing HIV CTL immunodominance
-
批准号:6904644
-
项目类别:
-
资助金额:$26.25万
-
财政年份:2004
-
负责人:Sylvie Le Gall
-
依托单位:
Role of antigen processing HIV CTL immunodominance
-
批准号:6843226
-
项目类别:
-
资助金额:$25.63万
-
财政年份:2004
-
负责人:Sylvie Le Gall
-
依托单位:
海外基金